[go: up one dir, main page]

BRPI0411226A - composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto - Google Patents

composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto

Info

Publication number
BRPI0411226A
BRPI0411226A BRPI0411226-1A BRPI0411226A BRPI0411226A BR PI0411226 A BRPI0411226 A BR PI0411226A BR PI0411226 A BRPI0411226 A BR PI0411226A BR PI0411226 A BRPI0411226 A BR PI0411226A
Authority
BR
Brazil
Prior art keywords
compound
preparation
pharmaceutical composition
warm
blooded animal
Prior art date
Application number
BRPI0411226-1A
Other languages
English (en)
Inventor
Ziping Liu
Daniel Page
Christopher Walpole
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0411226A publication Critical patent/BRPI0411226A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA A TERAPIA CONTRA DOR EM UM ANIMAL DE SANGUE QUENTE, E PARA A PREPARAçãO DE UM COMPOSTO". Compostos da Fórmula (I) ou seus sais farmaceuticamente aceitáveis: em que R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ e Z, são como definidos na especificação bem como os sais e as composições farmacêuticas que incluem os compostos são preparados. Estes são úteis na terapia, em particular, no controle da dor.
BRPI0411226-1A 2003-06-10 2004-06-09 composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto BRPI0411226A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301699A SE0301699D0 (sv) 2003-06-10 2003-06-10 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
PCT/GB2004/002427 WO2004108688A1 (en) 2003-06-10 2004-06-09 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0411226A true BRPI0411226A (pt) 2006-07-18

Family

ID=29212433

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411226-1A BRPI0411226A (pt) 2003-06-10 2004-06-09 composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto

Country Status (24)

Country Link
US (1) US7517898B2 (pt)
EP (1) EP1636193A1 (pt)
JP (1) JP2006527247A (pt)
KR (1) KR20060017863A (pt)
CN (2) CN1805940A (pt)
AR (1) AR044665A1 (pt)
AU (1) AU2004245296B2 (pt)
BR (1) BRPI0411226A (pt)
CA (1) CA2528924A1 (pt)
CO (1) CO5660261A2 (pt)
IL (1) IL172027A0 (pt)
IS (1) IS8220A (pt)
MX (1) MXPA05013050A (pt)
MY (1) MY139676A (pt)
NO (1) NO20060146L (pt)
NZ (1) NZ543632A (pt)
RU (1) RU2329254C2 (pt)
SA (1) SA04250161B1 (pt)
SE (1) SE0301699D0 (pt)
TW (1) TW200504030A (pt)
UA (1) UA83832C2 (pt)
UY (1) UY28357A1 (pt)
WO (1) WO2004108688A1 (pt)
ZA (1) ZA200509869B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE545644T1 (de) 2004-09-24 2012-03-15 Astrazeneca Ab Benzimidazolderivate, diese enthaltende zusammensetzungen, herstellung davon und anwendungen davon i
EP1912930A4 (en) * 2005-07-29 2010-04-14 Astrazeneca Ab PROCESS FOR PREPARING GEMINAL ((DIFLUORCYCLOALKYL) METHYL) AMINE
BRPI0707979A2 (pt) * 2006-02-20 2011-05-17 Astellas Pharma Cin derivado de amida ou sal deste
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
CA2709883A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
US20130196990A1 (en) * 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
PT2897939T (pt) 2012-09-21 2017-05-04 Sanofi Sa Derivados de amida do ácido benzoimidazol-carboxílico para tratamento de doenças metabólicas ou cardiovasculares
BR112017019453A2 (pt) 2015-03-13 2018-05-15 Forma Therapeutics Inc compostos e composições de alfa-cinamida como inibidores de hdac8

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
JP3295277B2 (ja) * 1994-06-01 2002-06-24 呉羽化学工業株式会社 抗腎疾患剤及びベンズイミダゾール誘導体
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7196095B2 (en) * 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
SE0301698D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Also Published As

Publication number Publication date
SA04250161B1 (ar) 2009-04-18
WO2004108688A1 (en) 2004-12-16
MXPA05013050A (es) 2006-03-02
TW200504030A (en) 2005-02-01
NO20060146L (no) 2006-03-07
UY28357A1 (es) 2005-01-31
UA83832C2 (ru) 2008-08-26
IL172027A0 (en) 2011-08-01
SE0301699D0 (sv) 2003-06-10
IS8220A (is) 2006-01-04
ZA200509869B (en) 2006-11-29
NZ543632A (en) 2009-02-28
RU2005138371A (ru) 2006-07-27
CN1805940A (zh) 2006-07-19
KR20060017863A (ko) 2006-02-27
CO5660261A2 (es) 2006-07-31
AU2004245296B2 (en) 2008-05-22
RU2329254C2 (ru) 2008-07-20
CA2528924A1 (en) 2004-12-16
EP1636193A1 (en) 2006-03-22
JP2006527247A (ja) 2006-11-30
AR044665A1 (es) 2005-09-21
US7517898B2 (en) 2009-04-14
AU2004245296A1 (en) 2004-12-16
US20070060583A1 (en) 2007-03-15
MY139676A (en) 2009-10-30
CN101328151A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
BRPI0411246A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto
BRPI0414780A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia da dor em um animal de sangue quente, e para preparar um composto
BRPI0411226A (pt) composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
BRPI0514035A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0511531A (pt) composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto
BRPI0510599A (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, uso de um composto, e método para o tratamento e a profilaxia de doenças
BR0208907A (pt) Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto.
BRPI0514032A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0315320A (pt) Composto ou sais farmaceuticamente aceitáveis dos mesmos, uso de um composto, composição farmacêutica, e, métodos para a terapia de dor em um animal de sangue quente e para produzir um composto
BR0315995A (pt) Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BRPI0514036A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
BRPI0515897A (pt) composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
BRPI0406614A (pt) Composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor em um animal de sangue quente e para a terapia de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto
BR0315998A (pt) Composto, uso de mesmo, composição farmacêutica, métodos para a terapia da dor e de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto
BRPI0408689B8 (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
BRPI0515860B8 (pt) derivados de tetralin e indano, seus usos, e composição farmacêutica
BRPI0514014A (pt) composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor, de ansiedade, e de mal de parkinson em um animal de sangue quente, e, processo para a preparação de um composto
BRPI0506702A (pt) composto, uso do mesmo, composição farmacêutica, método para a terapia de dor, e de distúrbios gatrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto
BRPI0410353A (pt) composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e da ansiedade em um animal de sangue quente, e, processo para preparar um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.